Search
Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnIt is a topical solution for the treatment of toenail infections. Systemic treatments may be considered more effective. … It is not approved for the treatment of onychomycosis in the United States or Canada.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseAtractylodes lancea root oil
go.drugbank.com/drugs/DB14338ApprovedIt is not an approved drug.
Mixtures: O Hui White Extreme Blemish BalmZalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnThis modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalMaralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat]. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsGemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseDextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Cytochrome P-450 SubstratesRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseALT-P1
go.drugbank.com/drugs/DB18485InvestigationalALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates